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Background: Traumatic brain injury (TBI) is commonly accompanied by intracranial bleeding which can worsen
after hospital admission. Tranexamic acid (TXA) has been shown to reduce bleeding in elective surgery and there is
evidence that short courses of TXA can reduce rebleeding in spontaneous intracranial haemorrhage. We aimed to
determine the effectiveness and safety of TXA in preventing progressive intracranial haemorrhage in TBI.
Methods: This is a double blinded, placebo controlled randomized trial. We enrolled 238 patients older than
16 years with moderate to severe TBI (post-resuscitation Glasgow Coma Scale (GCS) 4 to 12) who had a
computerized tomography (CT) brain scan within eight hours of injury and in whom there was no immediate
indication for surgery. We excluded patients if they had a coagulopathy or a serum creatinine over than 2.0
milligrams%. The treatment was a single dose of 2 grams of TXA in addition to other standard treatments. The
primary outcome was progressive intracranial haemorrhage (PIH) which was defined as an intracranial haemorrhage
seen on the second CT scan that was not seen on the first CT scan, or an intracranial haemorrhage seen on the first
scan that had expanded by 25% or more on any dimension (height, length, or width) on the second scan.
Results: Progressive intracranial haemorrhage was present in 21 (18%) of 120 patients allocated to TXA and in 32
(27%) of 118 patients allocated to placebo. The difference was not statistically significant [RR = 0.65 (95% CI 0.40 to
1.05)]. There were no significant difference in the risk of death from all causes in patients allocated to TXA
compared with placebo [RR = 0.69 (95% CI 0.35 to 1.39)] and the risk of unfavourable outcome on the Glasgow
Outcome Scale [RR = 0.76 (95% CI 0.46 to 1.27)]. There was no evidence of increased risk of thromboembolic events
in those patients allocated to TXA.
Conclusions: TXA may reduce PIH in patients with TBI; however, the difference was not statistically significant in
this trial. Large clinical trials are needed to confirm and to assess the effect of TXA on death or disability after TBI.
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Each year, world-wide more than 1.5 million people die
and about 10 million people are hospitalized following
traumatic brain injury (TBI) [1]. Many survivors experi-
enced long term disability [2]. In Thailand, each year
around 8,000 people died following acute TBI and tens of
thousands were hospitalized. A follow up study of 418 pa-
tients who were admitted to Khon Kaen regional hospital
following TBI found that 29% of patients were either dead
or severely disabled six months following the injury [3].
TBI is commonly accompanied by intracranial bleed-
ing which occurs in 25% to 45%, 3% to 12% and 0.2% of
severe, moderate and mild TBI cases respectively [4].
There were evidences indicating that this bleeding can
develop or continue after hospital admission and that
larger bleeds have a worse prognosis [5–12]. Delayed en-
largement of traumatic intraparenchymal contusions and
hematomas is the most common cause of clinical deteri-
oration and death in patients who had a lucid interval
after TBI [8,13].
A systematic review of randomized controlled trials
(RCT) shows that antifibrinolytic agents are effective in
reducing bleeding in elective surgery. The review sum-
marized data from 211 RCTs involving 20,781 partici-
pants showed that both Aprotinin and Tranexamic acid
(TXA) reduced the need for blood transfusion in elective
surgery by about one third [RR = 0.61 (95% CI 0.54 to
0.69)] with no evidences of increased adverse effects
[14]. If antifibrinolytics reduced intracranial bleeding in
patients with TBI, this would have important clinical im-
plications. However, a systematic review of haemostatic
drugs in patients with TBI found no RCTs [15].
There were some evidences on the use of TXA in
patients with spontaneous aneurysmal intracranial bleed-
ing. A systematic review of RCTs of TXA in aneurysmal
haemorrhage found that although rebleeding was reduced
by 45% [odds ratio = 0.55 (95% CI 0.42 to 0.71)], this bene-
fit was offset by cerebral ischaemia such that there was no
overall patients benefit [16]. However, these trials used
high doses TXA for about six weeks and it has been sug-
gested that a shorter and lower dose might prevent
rebleeding whilst avoiding the risk of ischaemia. Indeed,
since the review was published a trial of early short course
(3 days) TXA showed that it reduced rebleeding from
10.8% to 2.4% without ischaemic adverse effects [17].
We conducted a double blind randomized controlled
trials to evaluate the effect of early short course TXA on
the occurrence of progressive intracranial haemorrhage
(PIH) in patients with TBI treated at a large regional
trauma centre in rural Thailand.
Methods
A randomized, double-blind, placebo-controlled, parallel
group trial was conducted. The trial protocol was approvedby the Khon Kaen hospital’s ethics committee and the
Khon Kaen University’s ethics committee. The trial proto-
col was registered with www.clinicaltrials.gov with the trial
identifier NCT00755209. All written informed consent
forms were obtained from legally acceptable representative
of comatose participants.
Participants
All patients, older than 16 years, with moderate to severe
TBI (post-resuscitation Glasgow Coma Scale (GCS) 4 to
12) who had a computerized tomography (CT) brain scan
performed within eight hours of injury, and whom there
was no immediate indication for surgery, were eligible for
inclusion. There were both of isolated TBI and polytrauma
patients whom there were critical concern for TBI manage-
ment during the admission period. Patients were excluded
if they were pregnant, had evidences of coagulopathy,
known to be receiving a medication which affects haemo-
stasis, or had a serum creatinine over than 2 mg/decilitre.
Coagulopathy was considered present if any of the follow-
ing hematological parameters were observed: (1) platelet
count less than 100,000 cells/mm3; (2) Prothrombin time
(PT) or international normalized ratio (INR) prolonged
more than 1.5 times normal value; (3) activated partial
thromboplastin time (aPTT) more than 10 seconds greater
than normal value. Coagulopathy was a risk factor for
developing PIH and mortality in previous studies
[10,11,18–22] or recent reports [23,24]. Hence it was
confounding factor to be controlled by exclusion.
Intervention
Patients were randomly allocated to receive TXA (load-
ing dose of 1.0 gram over 30 minutes followed by a
maintenance dose of 1.0 gram infused over eight hours)
or matching placebo. The placebo was sterile water and
was purchased on the open market in Thailand.Study outcomes
The primary outcome was progressive intracranial haem-
orrhage. It would have more association to therapeutic ef-
fect of given tranexamic acid than other outcomes in this
study [25]. Moreover it was a significant source or link to
morbidity and mortality in TBI [8,10,18–20,26]. PIH was
defined as an intracranial haemorrhage seen on the second
CT scan that was not seen on the first CT scan, or an
intracranial haemorrhage seen on the first scan that had
expanded by 25% or more on any dimension (height,
length, or width) on the second scan. Progressive pressure
effect was defined as either an increase in midline shift of
greater than 1 mm or an increase in basal cistern between
the first and second CT scan. The second CT scan was to
be taken 24 hours ± 8 hours after the first CT scan. Im-
proved Glasgow Coma Scale (GCS) motor score was also
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ical and radiological progression at 24 hours.
The presence or absence of PIH was assessed by two in-
dependent readers. Both were neurosurgeons at KKH with
experiences in reading posttraumatic CT scans. When
there was disagreement about the presence or absence of
PIH this was resolved by a third neurosurgeon reader.
Inter-rater reliability was assessed by kappa statistic.
Secondary outcomes were death, functional status
assessed using the Glasgow Outcome Scale (GOS) at hos-
pital discharge, blood transfusion, neurosurgical operation
and any in-hospital thromboembolic events (myocardial
infarction, pulmonary embolism, deep vein thrombosis,
and stroke).
Sample size
We planned to randomize approximately 240 patients,
120 to each group. We estimated that the proportion of
patients with PIH would be 30% in the placebo group
and that TXA would reduce to be 15%. A trial with 240
patients would have about 80% power at the 0.05 level
of significance (two-sided test) to detect a treatment ef-
fect of this magnitude.
Randomisation and blinding
The randomisation sequence (with a randomly varied
block size) was generated from a computer by a person
who was not involved with the trial and this sequence
was used to prepare the sequentially numbered treat-
ment packs. Whenever an eligible patient was recruited,
the recruiting clinician asked that the next sequentially
numbered sealed opaque treatment pack be opened and
that the trial loading dose and maintenance infusion be
prepared and sent to the relevant ward. This preparation
was done out of sight of the recruiting clinician and re-
search participants by nurses who were not involved in
the trial. Each treatment pack contained unlabelled vials
of either drug or placebo. Although drug and placebo
vials contained an identical amount of colorless solution,
there was a small size discrepancy between the drug and
placebo vials. It was for this reason that the vials were
enclosed within sequentially numbered sealed opaque
envelopes that were opened by nurses who were not in-
volved in the trial. This approach ensured good alloca-
tion concealment and also ensured that those caring for
the patient and those conducting the trial did not know
the assigned treatment. The allocation scheme was kept
confidential from all research participants until the end
of the study.
Statistical methods
The primary analysis was on an intention-to-treat (ITT)
basis with complete case analysis for other outcomes
and was done using STATA software version 10.0. Thepresence or absence of PIH was analyzed as a dichotom-
ous variable. The Glasgow Outcome Scale was also di-
chotomized such that death, persistent vegetative state,
and severe disability constituted an unfavorable outcome
while favorable outcome included moderate disability
and good recovery. We calculated relative risks, risk dif-
ference with their 95% confidence intervals and hypoth-
esis testing between the two treatment groups.
Results
Patient recruitment
Figure 1 shows the participant flow into the trial. The first
patient was recruited on the 23rd October 2008 and the
last patient on 14th August 2009 by which time a total of
238 patients had been included in the trial. All patients re-
ceived the allocated trial treatments (TXA or placebo) and
there were no protocol violations. There were nine pa-
tients for whom a second CT scan could not be obtained:
seven patients died before the second CT scan, one patient
could not be scanned because of agitation, and one patient
refused the second scan. There were two consents with-
drawal in the placebo group after randomization because
they were signed by the unauthorized relatives. The re-
lated ethic committees were informed with an agreement
for this exclusion. The inter-rater reliability of the assess-
ment of the presence or absence of PIH was high with a
kappa statistic of 0.95. The patients were enrolled with
comparable profile including about mean age (40 years),
male gender (80%), injury onset (within 7 hours), associ-
ated organ injury with injury severity score 24 (range from
9–43) and initial haematocrit level (38 volumes%) with
moderately severe GCS severity. There were similar pres-
sures effects finding of the first CT scan in both groups.
Treatment and control groups were approximately bal-
anced with respect to baseline characteristics (Table 1).
Table 2 shows the effect of TXA on the study outcomes
by the intention to treat analysis with assuming poor out-
come which is used to represent the effectiveness of treat-
ment effect. Progressive intracranial haemorrhage was
present in 21 (18%) of patients allocated to TXA and in 32
(27%) of patients allocated to placebo. The difference was
not statistically significant [RR = 0.65 (95% CI 0.40 to
1.05)]. The relative risk of death from all causes in patients
allocated to TXA compared with placebo was 0.69 (95%
CI 0.35 to 1.39) and the relative risk for unfavourable out-
come on the Glasgow Outcome Scale was 0.76 (95% CI
0.46 to 1.27). The relative risk of blood transfusion need in
patients allocated to TXA compared with placebo was
0.92 (95% CI 0.61 to 1.40). Although we had informed the
clinical condition and proposed for emergency neurosur-
gical operation in all patients with PIH to their relatives.
The neurosurgical interventions were not done in placebo
group because the patients’ relatives did not allow us
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Allocated to TXA (n = 120) Allocated to placebo (n =120)
Assessed for eligibility (n = 2,922)
Received TXA (n =120) Received placebo (n =120)
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(dead 4)
PIH analysis (n =115)
Secondary outcomes (n=120)
PIH analysis (n =114)
Secondary outcomes (n=118)
2 consents withdrawn 
(unauthorized relatives)
Figure 1 Participant flow.
Table 1 Baseline characteristics
Characteristics TXA (n =120) Placebo (n = 118)
Age at randomization (years) 34.8 (16.0) 34.1 (15.3)
Male 103 (86%) 107 (91%)
Glasgow coma scale (GCS) severity: Moderate (9 – 12) Severe (4 – 8) 52 (53%) 47 (47%)
68 (49%) 71 (51%)
Baseline haematocrit (volume %) 38 (7.4) 38 (6.7)
Time since injury (hours) 6.6 (1.69) 7.1 1.29)
Isolated TBI injury 20 (17%) 16 (14%)
Polytrauma with TBI injury 100 (83%) 102 (86%)
Mean injury severity score (range) 23.3 (9–43) 24.8 (9–43)
Midline shift (>3 mm) on first CT (mm) 2 (0.02%) 3 (0.03%)
Basal cistern compression on first CT 54 (45%) 53 (45%)
Yutthakasemsunt et al. BMC Emergency Medicine 2013, 13:20 Page 4 of 7
http://www.biomedcentral.com/1471-227X/13/20
Table 2 Study outcomes
Outcomes TXA Placebo RD RR
(n = 120) (n = 118) [95% CI] [95% CI]
Progressive intracranial haemorrhage (PIH) 21 (18%) 32 (27%) −0.10 0.65
moderate TBI (n = 24) 7 (6%) 17 (14%) [(−0.20)- [0.40-1.05]
severe TBI (n = 20) 9 (8%) 11 (9%) (−0.01)]
indicated neurosurgery 6 (5%) 6 (5%)
Increase in pressure effect* *11 (10%) 12 (11%) −0.01 0.91
[(−0.09) – 0.07] [0.42-1.97]
Improved GCS motor score at 24 hours 37 (31%) 37 (31%) −0.01 0.98
[(−0.12) – 0.11] [0.67-1.44]
Neurosurgical intervention 3 (3%) 0 0.03 —
[(−0.00) – 0.05] —
Blood products transfusion 31 (26%) 33 (28%) −0.02 0.92
[(−0.13) – 0.09] [0.61-1.40]
Death 12 (10%) 17 (14%) −0.04 0.69
[(−0.13) – 0.04] [0.35-1.39]
Unfavorable (GOS) outcome 21 (18%) 27 (23%) −0.05 0.76
[(−0.16) – 0.05] [0.46-1.27]
Adverse events
Stroke 0 3 — —
Pulmonary embolus 0 0 — —
Deep vein thrombosis 0 0 — —
Gastrointestinal bleeding 0 1 — —
*Denominator for outcomes is 114 for TXA group and 115 for placebo group. This is an analysis based on complete case analysis that is not assumed the
missing outcome.
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were very few adverse effects in both groups. There was
no patient in TXA group who developed vascular occlu-
sion event in this study.
Table 3 shows the effect of various methods of handling
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Principal findings
We found a statistically insignificant difference but with
a trend towards significant reduction in the risk of PIH
in patients allocated to TXA without evidence of in-
creased risk of thrombotic adverse events. The risks of
death and of unfavorable outcome on the Glasgow Out-
come Score were lower for patients allocated to TXA.
The safety of early short course treatment of TXA in
our TBI patients was compatible to no increasing risk of
non-fatal vascular occlusive events with early short
course treatment of TXA in traumatic bleeding patients
in CRASH2 trial [27].
Strengths and weaknesses
This is the leading randomized trial to examine the effect-
iveness of the early administration of a short course of
TXA in patients with acute TBI. We are aware of a recent
study publication of CRASH2 trial and we anticipate that
the results of all relevant trials will ultimately be combined
in the Cochrane systematic review of haemostatic drugs
for TBI [15]. Our trial was properly randomized with good
allocation concealment. The timing of the second CT scan
was pre-specified in the protocol and all outcome mea-
surements were made without knowledge of treatment al-
location. The main weakness of our study is the low
power to estimate the effect of TXA on clinical outcomes.
In particular, although our study has shown statistically in-
significant difference that TXA may reduce PIH, because
of the low powers to examine the effect of TXA on death
and on disability, the clinical implications of our findings
are still limited.
Another limitation is lacking to explore an effect of as-
sociated injury or injury severity score in multiple trauma
patients which was concerned in some studies [19,21]. We
precluded exploring this association to the treatment by
our limited sample size. Polytrauma subjects were almost
patients whom there was agreement from trauma care
team to concern treatment for TBI as same as isolated
TBI subjects at first moment. Therefore we assigned ser-
ious, critical and serious injury degree for moderate TBI,
severe TBI and other anatomical organ injuries in the cat-
egory of injury severity score assessment respectively. The
common associated injuries were extremity fracture, facial
fracture, rib or clavicular fracture and a few cases of other
chest injury or minor abdominal trauma.
Finally the exclusion of coagulopathy is also a limita-
tion of our study and this subject could be a point to
explore in further research.
PIH in TBI
Various terms have been used to describe the development
or enlargement of intracranial bleeding after TBI. Terms in-
clude delayed traumatic intracranial haemorrhage (DTICH)[7], expanding hematoma [19] and progressive hemorrhagic
injury [10]. In this paper we combined these concepts such
that we included both new haemorrhage and expanding
haemorrhage (progressive intracranial haemorrhage). Our
rationale was that both lesions may exacerbate intracranial
hypertension and the occurrence of both may be affected
by the administration of TXA.
Although patients were excluded if they had evidence
of coagulopathy at baseline the proportion of patients
with PIH among the patients was surprisingly high. Had
we not excluded coagulopathic patients it is likely that
the proportion of patients with PIH would have been
even higher. Previous estimates of the occurrence of PIH
vary widely from 7% to 60% [20]. These differences are
likely to reflect difference in timing of the CT scan, clin-
ical setting and diagnostic criteria. Nevertheless, given
the relatively high prevalence of PIH in patients with
TBI observed in this study the potential for TXA to im-
prove clinical outcomes could be high.
Methods of handling missing response in trial
We summarize the result of handling missing outcome
for the primary outcome in Table 3.
Conclusions
We have not shown that TXA improves clinical outcomes
and this information would be required in order to make
any recommendation about the use of TXA in clinical
practice. Our results have important implications for re-
search. If an early short course of TXA could be demon-
strated to improve clinical outcomes after TBI without
any important adverse effects, then this treatment, because
it is cheap and widely practicable, could contribute im-
portantly to reducing mortality and disability after TBI.
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